Who
Pablo J. Cagnoni
President, Global Head of R&D
Company insider
Files Form 4 as: President, Global Head of R&D, Incyte; Director, Fusion Pharmaceuticals; CEO and President, Rubius Therapeutics; Director, CRISPR Therapeutics AG; EVP, Global R&D and Tech Ops, Onyx Pharmaceuticals; Sr. VP, Chief Medical Officer, Allos Therapeutics; VP & Chief Medical Officer, Osi Pharmaceuticals.
In numbers
- Trades disclosed
- 161
- Buys
- 1
- Sells
- 19
- Bought
- $99K
- Sold
- $30.4M
- Companies
- 7
- Companies where not an officer
- 2
- First trade
- 13 Dec 2006
- Last trade
- 15 Oct 2026
- Last filed
- 19 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Oct 2026filed 19 Oct 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code M | $60K839 at $71.93 | filing |
| 15 Oct 2026filed 19 Oct 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code M | $26K423 at $61.76 | filing |
| 15 Oct 2026filed 19 Oct 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code M | $28K455 at $61.18 | filing |
| 15 Oct 2026filed 19 Oct 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code M | $59K925 at $64.25 | filing |
| 15 Oct 2026filed 19 Oct 2026 | INCY IncyteLife-science tools | SEC FORM 4 Sold | $298K2,642 at $112.71 | filing |
| 15 Oct 2026filed 19 Oct 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code M | —839 at $0.00 | filing |
| 15 Oct 2026filed 19 Oct 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code M | —423 at $0.00 | filing |
| 15 Oct 2026filed 19 Oct 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code M | —455 at $0.00 | filing |
| 15 Oct 2026filed 19 Oct 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code M | —925 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code M | $183K2,957 at $61.76 | filing |
| 15 Sep 2026filed 17 Sep 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code M | —9,233 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code M | $278K4,551 at $61.18 | filing |
| 15 Sep 2026filed 17 Sep 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code M | $416K6,477 at $64.25 | filing |
| 15 Sep 2026filed 17 Sep 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code M | —2,957 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code M | —4,551 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code M | —6,477 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code M | —9,233 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code M | $664K9,233 at $71.93 | filing |
| 15 Sep 2026filed 17 Sep 2026 | INCY IncyteLife-science tools | SEC FORM 4 Sold | $1.1M9,233 at $120.50 | filing |
| 15 Sep 2026filed 17 Sep 2026 | INCY IncyteLife-science tools | SEC FORM 4 Sold | $1.7M13,985 at $120.49 | filing |
News
Comparing Madrigal Pharmaceuticals (NASDAQ:MDGL) and Incyte (NASDAQ:INCY)INCY · themarketsdaily.com · 20 Oct 2026
0 headlines in the last 90 days name Pablo J. Cagnoni; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.